首页> 美国卫生研究院文献>The Journal of Clinical Investigation >Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression avidity and vaccine formulation. The Collaborative Vaccine Study Group.
【2h】

Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression avidity and vaccine formulation. The Collaborative Vaccine Study Group.

机译:接种流感嗜血杆菌b型多糖-蛋白质结合物的婴儿的抗体反应中的可变区表达。新的λ轻链相关的独特型的描述以及独特型表达亲和力和疫苗制剂之间的关系。疫苗合作研究小组。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Haemophilus influenzae b polysaccharide (Hib PS)-protein conjugate vaccines differ chemically and immunologically. To determine whether anti-Hib PS variable region expression might differ according to vaccine formulation, infants were vaccinated at 2, 4, and 6 mo of age with Hib PS coupled to either meningococcal outer membrane protein complex (Hib PS-OMPC) or tetanus toxoid (Hib PS-T), or Hib PS oligomers coupled to a mutant diphtheria toxin (Oligo-CRM). Two anti-Hib PS idiotypes were measured in sera obtained after the third injection: HibId-1, expressed by anti-Hib PS antibodies having the kappa II-A2 variable region, and HibId-2, a newly defined cross-reactive idiotype associated with a subset of anti-Hib PS antibodies having lambda VII variable regions. HibId-1 was present in 33, 68, and 64% of infants given either Hib PS-OMPC, Oligo-CRM, or Hib PS-T, respectively (P < 0.001). The respective values for HibId-2 were 47, 18, and 10% (P = 0.001). Subjects who were vaccinated with Hib PS-OMPC or Hib PS-T and who produced detectable HibId-1-positive antibody, had significantly higher mean antibody avidity than subjects who did not produce HibId-1 positive antibodies. In contrast, Oligo-CRM evoked high avidity anti-Hib PS antibodies, irrespective of the idiotypic profile. These findings indicate fundamental differences in both variable region content and antibody quality elicited by different Hib PS conjugate vaccines.
机译:流感嗜血杆菌b多糖(Hib PS)-蛋白结合疫苗在化学和免疫学上有所不同。为了确定抗Hib PS可变区表达是否会根据疫苗的配方而有所不同,分别在2月,4日和6个月龄时给婴儿接种了Hib PS与脑膜炎球菌外膜蛋白复合物(Hib PS-OMPC)或破伤风类毒素(Hib PS-T)或与突变白喉毒素(Oligo-CRM)偶联的Hib PS低聚物。在第三次注射后获得的血清中测量了两种抗Hib PS独特型:由具有kappa II-A2可变区的抗Hib PS抗体表达的HibId-1,和与之相关的新定义的交叉反应独特型HibId-2具有λVII可变区的抗Hib PS抗体的子集。在分别接受Hib PS-OMPC,Oligo-CRM或Hib PS-T的婴儿中,分别有33%,68%和64%的婴儿存在HibId-1(P <0.001)。 HibId-2的相应值为47%,18%和10%(P = 0.001)。接种了Hib PS-OMPC或Hib PS-T疫苗并产生可检测到的HibId-1阳性抗体的受试者比没有产生HibId-1阳性抗体的受试者具有更高的平均抗体亲和力。相反,Oligo-CRM引起高亲和力的抗Hib PS抗体,而与独特型无关。这些发现表明,由不同的Hib PS缀合物疫苗引起的可变区含量和抗体质量的根本差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号